See more : LATHAM (JAMES) PLC 8% CUM PRF # (LTHP.L) Income Statement Analysis – Financial Results
Complete financial analysis of Modern Chinese Medicine Group Co., Ltd. (1643.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Modern Chinese Medicine Group Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Rushil Décor Limited (RUSHIL.BO) Income Statement Analysis – Financial Results
- Solanbridge Group, Inc. (SLNX) Income Statement Analysis – Financial Results
- Mayfield Childcare Limited (MFD.AX) Income Statement Analysis – Financial Results
- Central Bancompany, Inc. (CBCY) Income Statement Analysis – Financial Results
- WesCan Energy Corp. (WCE.V) Income Statement Analysis – Financial Results
Modern Chinese Medicine Group Co., Ltd. (1643.HK)
About Modern Chinese Medicine Group Co., Ltd.
Modern Chinese Medicine Group Co., Ltd., an investment holding company, produces and sells proprietary Chinese medicines for elderlies and aged-middle in the People's Republic of China. It offers therapeutics for the qi-deficiency and blood-statis, cardio-cerebrovascular, digestive and gastrointestinal, gynecological, respiratory system, and nervous system conditions. The company was founded in 1986 and is headquartered in Chengde, China. Modern Chinese Medicine Group Co., Ltd. is a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 344.08M | 399.66M | 360.70M | 308.69M | 218.77M | 173.51M | 106.47M |
| Cost of Revenue | 239.90M | 228.87M | 202.27M | 171.83M | 119.70M | 99.86M | 62.04M |
| Gross Profit | 104.18M | 170.79M | 158.43M | 136.86M | 99.07M | 73.66M | 44.43M |
| Gross Profit Ratio | 30.28% | 42.73% | 43.92% | 44.34% | 45.29% | 42.45% | 41.73% |
| Research & Development | 1.50M | 3.00M | 10.50M | 10.20M | 8.30M | 0.00 | 0.00 |
| General & Administrative | 11.43M | 16.26M | 22.91M | 36.19M | 12.70M | 239.00K | 238.00K |
| Selling & Marketing | 24.38M | 25.43M | 21.88M | 10.35M | 8.11M | 4.94M | 4.27M |
| SG&A | 35.81M | 41.69M | 44.79M | 46.54M | 20.80M | 5.18M | 4.51M |
| Other Expenses | 0.00 | 419.00K | 200.00K | 267.00K | 26.00K | 0.00 | 85.00K |
| Operating Expenses | 37.31M | 41.63M | 44.79M | 46.54M | 33.99M | 9.28M | 8.92M |
| Cost & Expenses | 277.21M | 270.50M | 247.06M | 218.37M | 153.69M | 109.14M | 70.96M |
| Interest Income | 906.00K | 675.00K | 421.00K | 136.00K | 146.00K | 130.00K | 253.00K |
| Interest Expense | 5.00K | 14.00K | 74.00K | 247.00K | 0.00 | 0.00 | 1.19M |
| Depreciation & Amortization | 6.44M | 5.69M | 2.72M | 1.84M | 1.55M | 1.72M | 1.80M |
| EBITDA | 74.75M | 130.03M | 117.02M | 92.56M | 66.81M | 66.22M | 37.76M |
| EBITDA Ratio | 21.73% | 32.54% | 32.44% | 29.98% | 30.54% | 38.17% | 35.36% |
| Operating Income | 66.87M | 124.34M | 114.30M | 90.73M | 65.26M | 64.51M | 35.85M |
| Operating Income Ratio | 19.43% | 31.11% | 31.69% | 29.39% | 29.83% | 37.18% | 33.67% |
| Total Other Income/Expenses | 1.44M | -1.77M | 11.08M | -4.01M | 174.00K | -1.82M | -2.89M |
| Income Before Tax | 68.31M | 124.32M | 114.22M | 90.48M | 65.26M | 64.51M | 34.77M |
| Income Before Tax Ratio | 19.85% | 31.11% | 31.67% | 29.31% | 29.83% | 37.18% | 32.66% |
| Income Tax Expense | 19.51M | 36.50M | 32.45M | 26.90M | 19.02M | 16.27M | 8.89M |
| Net Income | 48.80M | 87.83M | 81.78M | 63.58M | 46.24M | 48.24M | 25.88M |
| Net Income Ratio | 14.18% | 21.98% | 22.67% | 20.60% | 21.14% | 27.80% | 24.31% |
| EPS | 0.08 | 0.15 | 0.14 | 0.11 | 0.08 | 0.08 | 0.04 |
| EPS Diluted | 0.08 | 0.15 | 0.14 | 0.11 | 0.08 | 0.08 | 0.04 |
| Weighted Avg Shares Out | 600.00M | 600.00M | 593.84M | 600.00M | 600.00M | 600.00M | 600.00M |
| Weighted Avg Shares Out (Dil) | 600.00M | 600.00M | 593.84M | 600.00M | 600.00M | 600.00M | 600.00M |
Source: https://incomestatements.info
Category: Stock Reports